Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 9, 2008, Pages 1558-1564

  Hennan, James K ^a   Morgan, G A ^a   Swillo, R E ^a   Antrilli, T M ^a   Mugford, C ^a   Vlasuk, G P ^a   Gardell, S J ^a   Crandall, D L ^a  

^a PFIZER INC   (United States)

Author keywords

Fibrinolysis; PAI 1; Thrombosis; Vascular injury

Indexed keywords

ADENOSINE DIPHOSPHATE; ALTEPLASE; ANTICOAGULANT AGENT; COLLAGEN; ENOXAPARIN; FERROUS CHLORIDE; PAI 039; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIPLAXTININ; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CAROTID ARTERY FLOW; CAROTID ARTERY THROMBOSIS; CAVA VEIN DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG UPTAKE; ECHOGRAPHY; MALE; MORNING DOSAGE; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VEIN BLOOD FLOW; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DISEASE MODELS, ANIMAL; INDOLEACETIC ACIDS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PROTHROMBIN TIME; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS;

EID: 49849096654     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03063.x     Document Type: Article

References (22)

1. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 12: 3114-24.
2. Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am J Pathol 1994; 5: 855-61.
3. Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution. J Biol Chem 1992; 24: 17128-35.
4. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994; 4: 2126-46.
5. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003; 19: 1545-64.
6. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 1995; 4: 1175-81.
7. van Giezen JJ, Wahlund G, Nerme V, Abrahamsson T. The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb Haemost 1997; 5: 964-9.
8. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 23: 3050-5.
9. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000; 13: 4212-5.
10. Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, Crandall DL. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: Design, synthesis, and preclinical characterization. J Med Chem 2004; 14: 3491-4.
11. Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL. Evaluation of PAI-039
12. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 4: 1465-72.
13. Stringer HA, van Swieten P, Heijnen HF, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 9: 1452-8.
14. Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006; 4: 2710-5.
15. Gorlatova NV, Cale JM, Elokdah H, Li D, Fan K, Warnock M, Crandall DL, Lawrence DA. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 2007; 12: 9288-96.
16. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation 2001; 103: 576-83.
17. Preissner KT, Holzhüter S, Justus C, Müller-Berghaus G. Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 1989; 74: 1989-96.
18. Seiffert D, Schleef RR. Two functionally distinct pools of vitronectin (Vn) in the blood circulation: Identification of a heparin-binding competent population of Vn within platelet alpha-granules. Blood 1996; 88: 552-60.
19. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
20. Koschnick S, Konstantinides S, Schafer K, Crain K, Loskutoff DJ. Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin. J Thromb Haemost 2005; 3: 2290-5.
21. Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 1: 305-12.
22. Charlton PA, Faint RW, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, Machin S, Bevan P. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost 1996; 5: 808-15.